cd19/cd20 dual-car-t cells
Aggressive B-Cell Non-Hodgkin Lymphoma
Explore 28 assets in Aggressive B-Cell Non-Hodgkin Lymphoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Chinese PLA General Hospital
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04553393CT.gov Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Aggressive B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd19/cd20 dual-car-t cells (this asset) | Chinese PLA General Hospital | P1/2 | CCC · 48 |
| Rituximab | Shanghai EpimAb Biotherapeutics Co., Ltd. | P3 | BB |
| Lipegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | BB |
| (+)-Vincristine | Universität des Saarlandes | P3 | B |
| Pegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | B |
| Obinutuzumab | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Acalabrutinib | Patrick C. Johnson, MD | P2 | B |
| Zanubrutinib | Prelude Therapeutics | P2 | B |
| Oxaliplatin | Shanghai EpimAb Biotherapeutics Co., Ltd. | P2 | B |
+42 more in the Aggressive B-Cell Non-Hodgkin Lymphoma cohort
Other indications for cd19/cd20 dual-car-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P1/2 | B · 56 |
| B-Cell Neoplasm | — | P1/2 | CCC · 48 |
| B-Cell Acute Lymphoblastic Leukemia | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd19/cd20 dual-car-t cells in Aggressive B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19cd20-dual-car-t-cells-aggressive-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →